Market Cap: $13.35B
JP
Jazz Pharmaceuticals plc
JAZZ
NASDAQUSD
Market Cap: $13.35B
Jazz Pharmaceuticals plc (Ticker: JAZZ) showcases its commitment to advancing care for patients with narcolepsy and idiopathic hypersomnia (IH) through recent presentations at SLEEP 2026, emphasizing…
Jazz Pharmaceuticals plc (Ticker: JAZZ) showcases its commitment to improving patient outcomes as it announces significant advancements in oncology following successful clinical trial results for its…
Jazz Pharmaceuticals: Empowering Patient Lives Through Innovation Jazz Pharmaceuticals plc is actively reshaping the landscape of biopharmaceuticals by focusing on the development of innovative treatm…
Navigating Nutritional Education: Jazz Pharmaceuticals Partners with ANA Jazz Pharmaceuticals plc takes a significant step in addressing the health needs of individuals with narcolepsy and idiopathic…
Innovative Nutritional Initiative to Support Patients with Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals is taking a significant step in understanding and addressing the dietary needs of…
Jazz Pharmaceuticals Advances Oncology Research at 2026 AACR Annual Meeting Jazz Pharmaceuticals plc is set to make a significant impact at the 2026 American Association for Cancer Research (AACR) Ann…
Jazz Pharmaceuticals Focuses on Advancing Rare Disease Treatments In recent days, Jazz Pharmaceuticals plc continues to make significant strides in the realm of rare disease treatments, underscoring i…
Jazz Pharmaceuticals Faces Mixed Analyst Sentiment Amid Competitive Landscape Recent evaluations reveal a dichotomy of perspectives from analysts regarding Jazz Pharmaceuticals' outlook. Over the past…
Jazz Pharmaceuticals: Strong Q4 Performance Highlights Commitment to Innovation Jazz Pharmaceuticals plc reports impressive financial results for Q4 2026, showcasing the success of its growth strategy…
Jazz Pharmaceuticals Gears Up for Productive Fiscal Year Amid Encouraging Q4 Performance Jazz Pharmaceuticals plc, a leading player in the pharmaceutical industry, is positioned for a promising year a…
Jazz Pharmaceuticals Welcomes Thomas Riga as Chief Business Officer Amid Strategic Growth Plans Jazz Pharmaceuticals plc announces the appointment of Thomas Riga as Chief Business Officer, effective J…
Jazz Pharmaceuticals Sets Stage for Major Investor Engagements in January 2026 Jazz Pharmaceuticals plc, a leader in innovative therapies for serious diseases, announces its participation in two pivot…
Jazz Pharmaceuticals Prepares for Key Investor Events Highlighting Oncology Progress Jazz Pharmaceuticals plc is poised to showcase its commitment to advancing cancer treatment during two significant…
Growing Pains: Analyzing Jazz Pharmaceuticals' Short Interest Surge Jazz Pharmaceuticals plc finds itself in the spotlight as it confronts a significant rise in short interest, which has surged by 9.0…
AI-Driven Drug Development: A New Frontier for Life Sciences Iambic, a clinical-stage life science and technology company, recently announces a successful financing round that raises over $100 million…
AI-Driven Drug Development: A New Frontier for the Pharmaceutical Industry Iambic, a clinical-stage life science and technology company, has recently secured over $100 million in an oversubscribed fin…
Jazz Pharmaceuticals Focuses on Advancing Innovative Treatments Jazz Pharmaceuticals plc continues to prioritize the development and commercialization of innovative therapies to address unmet medical…
Jazz Pharmaceuticals Faces Industry Challenges Amid Earnings Season As the pharmaceutical sector braces for a wave of earnings reports, Jazz Pharmaceuticals plc finds itself in a landscape marked by b…
Jazz Pharmaceuticals Prepares for Critical Earnings Announcement Amidst Market Scrutiny Jazz Pharmaceuticals plc is gearing up for its quarterly earnings report scheduled for November 5, 2025, with an…
Jazz Pharmaceuticals Eyes Strategic Developments in CNS Drug Pipeline Jazz Pharmaceuticals plc focuses on advancing treatments for central nervous system (CNS) disorders, a sector characterized by rap…
Strategic Leadership Changes at Jazz Pharmaceuticals Signal Growth Aspirations Jazz Pharmaceuticals plc strengthens its leadership team with the appointment of Dr. Ted W. Love to its Board of Director…
Alkermes Acquires Avadel: A Strategic Move in the Biotech Landscape In a significant development within the pharmaceutical sector, Alkermes plc has announced its agreement to acquire Avadel Pharmaceut…
Analyst Perspectives on Jazz Pharmaceuticals: A Mixed Bag of Optimism and Caution In recent months, Jazz Pharmaceuticals plc finds itself under a spotlight as nine analysts provide a spectrum of ratin…
Jazz Pharmaceuticals: Navigating the Landscape of Small-Cap Growth Potential In the evolving landscape of small-cap stocks, Jazz Pharmaceuticals plc stands as a noteworthy player within the biopharmac…
Strategic Acquisition Signals Growth in Biotech Landscape for SciSparc Ltd. SciSparc Ltd. (NASDAQ: SPRC) recently announces a definitive agreement to acquire a controlling stake in Miza III Ventures I…